<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "http://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xml:lang="en" article-type="research-article" dtd-version="1.1">
<front>
<journal-meta>
<journal-id journal-id-type="pmc">BIOCELL</journal-id>
<journal-id journal-id-type="nlm-ta">BIOCELL</journal-id>
<journal-id journal-id-type="publisher-id">BIOCELL</journal-id>
<journal-title-group>
<journal-title>BIOCELL</journal-title>
</journal-title-group>
<issn pub-type="epub">1667-5746</issn>
<issn pub-type="ppub">0327-9545</issn>
<publisher>
<publisher-name>Tech Science Press</publisher-name>
<publisher-loc>USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">25048</article-id>
<article-id pub-id-type="doi">10.32604/biocell.2023.025048</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>MiR-194-5p suppresses the warburg effect in ovarian cancer cells through the IGF1R/PI3K/AKT axis</article-title><alt-title alt-title-type="left-running-head">MiR-194-5p suppresses the warburg effect in ovarian cancer cells through the IGF1R/PI3K/AKT axis</alt-title><alt-title alt-title-type="right-running-head">MiR-194-5p suppresses the Warburg effect</alt-title>
</title-group>
<contrib-group content-type="authors">
<contrib id="author-1" contrib-type="author">
<name name-style="western"><surname>DU</surname><given-names>LIJUN</given-names></name>
<xref ref-type="aff" rid="aff-1">1</xref>
</contrib>
<contrib id="author-2" contrib-type="author">
<name name-style="western"><surname>DOU</surname><given-names>KAIKAI</given-names></name>
<xref ref-type="aff" rid="aff-1">1</xref>
</contrib>
<contrib id="author-3" contrib-type="author">
<name name-style="western"><surname>LIANG</surname><given-names>NIANHAI</given-names></name>
<xref ref-type="aff" rid="aff-1">1</xref>
<xref ref-type="aff" rid="aff-2">2</xref>
</contrib>
<contrib id="author-4" contrib-type="author">
<name name-style="western"><surname>SUN</surname><given-names>JIANMIN</given-names></name>
<xref ref-type="aff" rid="aff-1">1</xref>
</contrib>
<contrib id="author-5" contrib-type="author" corresp="yes">
<name name-style="western"><surname>BAI</surname><given-names>RU</given-names></name>
<xref ref-type="aff" rid="aff-1">1</xref><email>bryw780109@163.com</email>
</contrib>
<aff id="aff-1"><label>1</label><institution>School of Basic Medicine, Ningxia Medical University</institution>, <addr-line>Yinchuan, 750004</addr-line>, <country>China</country></aff>
<aff id="aff-2"><label>2</label><institution>The Fifth People&#x2019;s Hospital of Ningxia</institution>, <addr-line>Shizuishan, 753000</addr-line>, <country>China</country></aff>
</contrib-group><author-notes><corresp id="cor1"><label>&#x002A;</label>Address correspondence to: Ru Bai, <email>bryw780109@163.com</email></corresp></author-notes>
<pub-date date-type="collection" publication-format="electronic"><year>2023</year></pub-date>
<pub-date date-type="pub" publication-format="electronic"><day>02</day><month>01</month><year>2023</year></pub-date>
<volume>47</volume>
<issue>3</issue>
<fpage>547</fpage>
<lpage>554</lpage>
<history>
<date date-type="received"><day>19</day><month>6</month><year>2022</year></date>
<date date-type="accepted"><day>06</day><month>10</month><year>2022</year></date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2023 Du et al.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Du et al.</copyright-holder>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:type="simple" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="TSP_BIOCELL_25048.pdf"></self-uri>
<abstract><sec><title>Background</title>
<p>The Warburg effect is considered as a hallmark of various types of cancers, while the regulatory mechanism is poorly understood. Our previous study demonstrated that miR-194-5p directly targets and regulates insulin-like growth factor1 receptor (IGF1R). In this study, we aimed to investigate the role of miR-194-5p in the regulation of the Warburg effect in ovarian cancer cells.</p>
</sec>
<sec><title>Methods</title>
<p>The stable ovarian cell lines with miR-194-5p overexpression or silencing IGF1R expression were established by lentivirus infection. ATP generation, glucose uptake, lactate production and extracellular acidification rate (ECAR) assay were used to analyze the effects of aerobic glycolysis in ovarian cancer cells. Gene expression was analyzed by quantitative polymerase chain reaction (qPCR) and western blot. Immunohistochemistry assays were performed to assess the expression of the IGF1R protein in ovarian cancer tissues.</p>
</sec>
<sec><title>Results</title>
<p>Overexpression of miR-194-5p or silencing IGF1R expression in ovarian cancer cells decreases ATP generation, glucose uptake, lactate production, and ECAR and inhibits both the mRNA and protein expression of PKM2, LDHA, GLUT1, and GLUT3. While the knockdown of miR-194-5p expression led to opposite results. Overexpression of miR-194-5p or silencing IGF1R expression suppressed the phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathway, whose activation can sustain aerobic glycolysis in cancer cells, and the knockdown of miR-194-5p expression promoted the activation of the PI3K/AKT pathway.</p>
</sec>
<sec><title>Conclusion</title>
<p>Our results suggest that miR-194-5p can inhibit the Warburg effect by negative regulation of IGF1R and further repression of the PI3K/AKT pathway, which provides a theoretical basis for further test of miR-194-5p as a target in the treatment of ovarian cancer.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>Ovarian cancer</kwd>
<kwd>Aerobic glycolysis</kwd>
<kwd>microRNA</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1"><title>Introduction</title>
<p>Ovarian cancer is a highly malignant tumor and is the number one killer among cancers of the female reproductive system that seriously threatens the health of women (<xref ref-type="bibr" rid="ref-1">Amin <italic>et al</italic>., 2019</xref>; <xref ref-type="bibr" rid="ref-4">Cabasag <italic>et al</italic>., 2020</xref>). Tumor reduction surgery combined with chemotherapy is widely applied in the treatment of ovarian cancer, while the five-year relative survival is less than 50% due to recurrence and drug resistance (<xref ref-type="bibr" rid="ref-1">Amin <italic>et al</italic>., 2019</xref>; <xref ref-type="bibr" rid="ref-16">Torre <italic>et al</italic>., 2018</xref>; <xref ref-type="bibr" rid="ref-5">Coburn <italic>et al</italic>., 2017</xref>; <xref ref-type="bibr" rid="ref-17">Tsibulak <italic>et al</italic>., 2019</xref>). Therefore, the development of new methods in the prognosis and treatment of ovarian cancer is of great importance.</p>
<p>Tumor cells rely on abnormal energy metabolism to promote rapid cell growth, invasion, and metastasis. Aerobic glycolysis is the common energy metabolic feature of cancer cells, and cancer cells provide energy by enhancing anaerobic fermentation (<xref ref-type="bibr" rid="ref-7">Hanahan and Weinberg, 2011</xref>). Tumor cells consume large amounts of glucose, and the glucose transporter (GLUT) transports glucose into tumor cells for glycolysis. After glucose is metabolized to pyruvate, aerobic oxidation occurs through lactate dehydrogenase (LDH), and pyruvate is catalyzed into lactic acid instead of the mitochondrial tricarboxylic acid cycle (<xref ref-type="bibr" rid="ref-13">Park <italic>et al</italic>., 2020</xref>; <xref ref-type="bibr" rid="ref-19">Vazquez <italic>et al</italic>., 2016</xref>), which was first observed by Warburg and named as the Warburg effect.</p>
<p>MicroRNAs (miRNAs) are endogenous short RNA of 20 to 24 nucleotides long that are widely expressed in eukaryotes and can induce the degradation of target mRNA or inhibit its translation by complementary pairing with target mRNA (<xref ref-type="bibr" rid="ref-14">Saliminejad <italic>et al</italic>., 2019</xref>; <xref ref-type="bibr" rid="ref-20">Vishnoi and Rani, 2017</xref>; <xref ref-type="bibr" rid="ref-9">He and Hannon, 2004</xref>). Accumulating evidence suggested that miRNAs are extensively involved in the regulation of ovarian cancer progression and development (<xref ref-type="bibr" rid="ref-26">Ghafouri-Farda <italic>et al</italic>., 2020</xref>). However, the regulatory mechanism of miRNA and the Warburg effect in ovarian cancer remains to be investigated.</p>
<p>In our study, we discovered that miR-194-5p affects the aerobic glycolysis of ovarian cancer cells, by which miR-194-5p suppresses aerobic glycolysis via the IGF1R/PI3K/AKT axis. Our finding would provide a rationale for screening the new molecular target of ovarian cancer.</p>
</sec>
<sec id="s2"><title>Materials and Methods</title>
<sec id="s2_1"><title>Cell cultures</title>
<p>Two human ovarian cancer cell lines, ES-2 and SKOV3, were cultured as previously described (<xref ref-type="bibr" rid="ref-3">Bai <italic>et al</italic>., 2020</xref>).</p>
</sec>
<sec id="s2_2"><title>Lentivirus infection and establishment of stable cell lines</title>
<p>ES-2 and SKOV3 cells were seeded in a six-well plate overnight and infected with lentiviruses expressing LV-miR-194-5p or LV-miR-194-5p-NC, LV-miR-194-5p-inhibition or LV-miR-194-5p-inhibition-NC, LV-IGF1R-RNAi or LV-IGF1R-RNAi-NC (GeneChem, Shanghai, China). After 72 h of infection, the cells were selected with 2 &#x03BC;g/mL puromycin for two weeks to establish stable cell lines.</p>
</sec>
<sec id="s2_3"><title>RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)</title>
<p>Total RNA was extracted using RNA Easy Fast Tissue/Cell Kit (TianGen, Beijing, China), followed by reverse transcription into cDNA using PrimeScript&#x2122; RT reagent Kit (Takara, Dalian, China). TB Green&#x00AE; Premix Ex Taq&#x2122; II (Takara, Dalian, China) was used to run qPCR. The primer sequences (listed in <xref ref-type="table" rid="table-1">Table 1</xref>) were designed and synthesized by Sangon Biotech (Shanghai, China). The expression of miRNA or mRNA was quantified by the 2<sup>&#x2013;&#x0394;&#x0394;CT</sup> method, using U6 as an internal reference gene for microRNA assays and &#x03B2;-actin as an internal reference gene for gene assays.</p>
<table-wrap id="table-1"><label>TABLE 1</label>
<caption><title>Primer sequence</title></caption>
<table><colgroup>
<col/>
<col/>
</colgroup>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequence (5&#x2032;-3&#x2032;)</th>
</tr>
</thead>
<tbody>
<tr>
<td><italic>miR-194-5p</italic></td>
<td>Forward: ACACTCCAGCTGGGTGTAACAGCAACTCCA<break/>Reverse: TGGTGTCGTGGAGTCG<break/>RT: CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCCACA</td>
</tr>
<tr>
<td><italic>U6</italic></td>
<td>Forward: CTCGCTTCGGAGCACATATACT<break/>Reverse: ACGCTTCACGAATTTGCGTGTC<break/>RT: GTCGTATCCAGTGCAGGGTCCGAGGTGCACTG GATACGACAAAATATGG</td>
</tr>
<tr>
<td><italic>PKM2</italic></td>
<td>Forward: ACTGGCATCATCTGTACCATTG<break/>Reverse: AGCCACATTCATTCCAGACTTA</td>
</tr>
<tr>
<td><italic>LDHA</italic></td>
<td>Forward: AGGTGATCAAACTCAAAGGCTA<break/>Reverse: CCCAAAATGCAAGGAACACTAA</td>
</tr>
<tr>
<td><italic>GLUT1</italic></td>
<td>Forward: CTCCTGGTGATGCTTAGTGCCTTG<break/>Reverse: GCTGTTGTTCCGAGTGGGCAGTG</td>
</tr>
<tr>
<td><italic>GLUT3</italic></td>
<td>Forward: TTCAATGCTGATTGTCAACCTG<break/>Reverse: GCATTTCAACCGACTTAGCTAC</td>
</tr>
<tr>
<td><italic>&#x03B2;-actin</italic></td>
<td>Forward: CCTGGCACCCAGCACAAT<break/>Reverse: GGGCCGGACTCGTCATAC</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2_4"><title>Western blots</title>
<p>The cells were lysed and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The protein was transferred to a polyvinylidene fluoride membrane and blocked using a blocking buffer. Then, the membranes were incubated with monoclonal primary antibodies respectively, including anti-insulin-like growth factor1 receptor (IGF1R; CST, USA), anti-phosphorylation of serine/threonine kinase (p-AKT; S473, CST, USA), anti-AKT (CST, USA) or &#x03B2;-actin (Bioss, Beijing, China). For the detection of the key genes or enzymes involved in glycolysis, we used polyclonal antibodies, including anti-pyruvate kinase M2 (anti-PKM2), anti-lactate dehydrogenase A (anti-LDHA), anti-glucose transporter 1 and 3 (anti-GLUT1, and GLUT3) (Proteintech, Wuhan, China). After washing, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody (Bioss, Beijing, China) and developed using the enhanced chemiluminescence kit (NCM Biotech, Suzhou, China). The signals were captured by Amersham Imager 600 (USA). The intensity of reference gene &#x03B2;-actin served as the loading control.</p>
</sec>
<sec id="s2_5"><title>Immunohistochemistry</title>
<p>The paraffin sections of ovarian cancer tissue were soaked in a series of xylene and graded alcohols and incubated in the boiling buffer containing ethylenediaminetetraacetic acid for antigen retrieval. To inhibit endogenous peroxidase, the sections were incubated in 3% H<sub>2</sub>O<sub>2</sub> solution for 8 min and blocked with goat serum. Then the sections were incubated with a primary antibody against IGF1R (Bioss, Beijing, China), followed by incubation with a secondary antibody (Bioss, Beijing, China). After hematoxylin staining, tissue sections were soaked in an alcohol gradient, followed by soaking in xylene. The images were captured by a microscope, and the target signals were quantified by the Image-J software (USA).</p>
</sec>
<sec id="s2_6"><title>Analysis of ATP generation</title>
<p>The concentration of ATP was examined using the Enhanced ATP Assay Kit (Beyotime, Shanghai, China). Each well of a twelve-well plate was seeded with 8 &#x00D7; 10<sup>4</sup> cells and lysed for 42 h. The 96-well plate was preincubated with 100 &#x03BC;L ATP assay buffer for 5 min, and 10 &#x03BC;L of supernatants were added for the determination of ATP concentration. The absorbance was read by a multifunctional microplate reader (PerkinElmer, USA) and calculated by substituting the assay values into the standard curve. The linear range of the assay was between 0.1 nM to 10 &#x00B5;M.</p>
</sec>
<sec id="s2_7"><title>Glucose uptake analysis</title>
<p>Glucose uptake was detected by Glucose Uptake Colorimetric Assay Kit (Biovision, USA). The cells were cultured overnight in a growth medium without serum and 100 &#x03BC;L of Krebs-Ringer-Phosphate-Hepes buffer containing 2% bovine serum albumin for 40 min. The cells were treated with 0.1 mg/mL insulin to activate the glucose transporter and 10 mM 2-deoxy-D-glucose (2-DG) for 20 min separately. To degrade endogenous NAD(P) and denature enzymes, cells were lysed in 90 &#x03BC;L extraction buffer at 90&#x00B0;C for 40 min and cooled down on the ice for 5 min. Then, neutralization buffer (12 mL) was mixed with 38 &#x03BC;l of Mix B and added to each well, and the absorbance was measured at 412 nm at 37&#x00B0;C by the multifunctional microplate reader. The standard glucose uptake curve was plotted using the standard well absorbance value, and then the glucose uptake level was calculated.</p>
</sec>
<sec id="s2_8"><title>Assessment of lactate production</title>
<p>The colorimetric lactate kit (Solarbio, Beijing, China) was used to measure lactate concentration. Cells (5 &#x00D7; 10<sup>6</sup> cells) were lysed in 1 mL of extraction buffer I through ultrasonic disruption and then centrifuged. Supernatants (700 &#x03BC;L) and extraction buffer II (150 &#x03BC;L) were mixed, followed by centrifugation at 10,000 g at 4&#x00B0;C for 10 min. Then, supernatants (10 &#x03BC;L) were mixed with assay buffer for 20 min at 37&#x00B0;C. The absorbance at 570 nm was read by a multifunctional microplate reader. The standard lactate solution curve was obtained by diluting 2.5, 1.25, 0.625, 0.3125, 0.15625, and 0.078 &#x00B5;mol/mL of the lactate standard into the 96-well plate. The linear range of the assay was between 0.05 mM to 20 mM.</p>
</sec>
<sec id="s2_9"><title>Extracellular acidification rate (ECAR) assays</title>
<p>Seahorse XF Glycolysis Stress Test Kit (Agilent, USA) was used to examine ECAR. Then, in the XFe24 microplate, (2 &#x00D7; 10<sup>4</sup>) cells were seeded. The cartridge sensor was hydrated overnight in a CO<sub>2</sub>-free incubator. Before detection with seahorse, the cells were treated with 2 mM glutamine for 1 h in a CO<sub>2</sub>-free incubator. Glucose (100 mM), oligomycin (100 &#x00B5;M), and 2-DG (500 mM) were added sequentially into each well and detected through Seahorse XFe24 Analyzer (Agilent, USA).</p>
</sec>
</sec>
<sec id="s3"><title>Statistical Analysis</title>
<p>Data from at least three independent experiments were expressed as the mean &#x00B1; SD. The data were analyzed by SPSS 26.0 software with the two-tailed Student&#x2019;s <italic>t</italic>-test; <italic>p</italic> &#x003C; 0.05 was considered statistically significant.</p>
</sec>
<sec id="s4"><title>Results</title>
<sec id="s4_1"><title>MiR-194-5p weakens the warburg effect in ovarian cancer cells</title>
<p>The tumor cells have a higher glucose uptake rate and produce more ATP and lactate than normal cells because of the Warburg effect. To detect the role of miR-194-5p in the Warburg effect in ovarian cancer cells, we established ovarian cancer cells with stable overexpression of miR-194-5p or its knockdown by lentivirus infection (<xref ref-type="fig" rid="fig-1">Fig. 1A</xref>). Further measurements showed that miR-194-5p overexpression decreases ATP generation (<xref ref-type="fig" rid="fig-1">Fig. 1B</xref>), glucose uptake (<xref ref-type="fig" rid="fig-1">Fig. 1C</xref>), and lactate production (<xref ref-type="fig" rid="fig-1">Fig. 1D</xref>), whereas knocked down of miR-194-5p expression exhibited the opposite effect. Consistently, examination of glycolytic metabolism showed that ECAR and maximum glycolytic capacity are significantly decreased in the cells with miR-194-5p overexpression, while downregulation of miR-194-5p expression increased ECAR and maximum glycolytic capacity (<xref ref-type="fig" rid="fig-1">Figs. 1E</xref> and <xref ref-type="fig" rid="fig-1">1F</xref>). These data thus indicated that miR-194-5p suppresses the Warburg effect in ovarian cancer cells.</p>
<fig id="fig-1">
<label>Figure 1</label>
<caption><title>miR-194-5p inhibits the Warburg effect in ovarian cancer cells. (A) qPCR to analyze miR-194-5p expression in stable ovarian cell lines with overexpression of miR-194-5p or knocked down miR-194-5p expression. U6 was used as the internal control. (B&#x2013;F) Quantification of ATP (B), level of glucose uptake (C), lactate concentration (D), ECAR (E), and glycolytic capacity (F) in the ovarian cells with miR-194-5p overexpression or miR-194-5p expression knocked down. (&#x002A;<italic>P</italic> &#x003C; 0.05; &#x002A;&#x002A;<italic>P</italic> &#x003C; 0.01, &#x002A;&#x002A;&#x002A;<italic>P</italic> &#x003C; 0.001). ECAR: extracellular acidification rate; qPCR: quantitative polymerase chain reaction.</title></caption>
<graphic mimetype="image" mime-subtype="tif" xlink:href="Biocell-47-25048-f001.tif"/>
</fig>
</sec>
<sec id="s4_2"><title>MiR-194-5p suppresses the glycolytic gene expression in ovarian cancer cells</title>
<p>Many key enzymes or genes of glycolytic metabolism are altered by the Warburg effect. Therefore, we assessed the mRNA and protein expression of PKM2, LDHA, GLUT1, and GLUT3 in ovarian cancer cells when miR-194-5p was overexpressed or its expression was knocked down. PKM2 determines whether glucose is channeled into the lactate-producing pathway. LDHA is a step-controlling enzyme that controls the last step of glycolysis by mediating the interconversion of pyruvate and lactate. GLUT1 and GLUT3 are two important glucose transporters involved in glycolysis in tumor cells (<xref ref-type="bibr" rid="ref-18">Vaupel and Multhoff, 2021</xref>). We observed that miR-194-5p overexpression reduces the mRNA (<xref ref-type="fig" rid="fig-2">Figs. 2A</xref>&#x2013;<xref ref-type="fig" rid="fig-2">2D</xref>) and protein (<xref ref-type="fig" rid="fig-2">Fig. 2E</xref>) expression of PKM2, LDHA, GLUT1, and GLUT3, whereas knockdown of miR-194-5p expression gives the opposite results.</p>
<fig id="fig-2">
<label>Figure 2</label>
<caption><title>miR-194-5p mediates the expression of key glycolytic genes in ovarian cancer cells. (A&#x2013;D) The mRNA expression of PKM2(A), LDHA(B), GLUT1(C), and GLUT3 (D) in the ovarian cells with miR-194-5p overexpression or miR-194-5p expression knocked down was detected by qPCR. &#x03B2;-actin was used as the internal control. (E) The protein expression of PKM2, LDHA, GLUT1, and GLUT3 in the ovarian cells with miR-194-5p overexpression or miR-194-5p expression knocked down was examined by western blotting. (&#x002A;<italic>P</italic> &#x003C; 0.05; &#x002A;&#x002A;<italic>P</italic> &#x003C; 0.01, &#x002A;&#x002A;&#x002A;<italic>P</italic> &#x003C; 0.001). PKM2: pyruvate kinase M2; LDHA: lactate dehydrogenase A; GLUT: glucose transporter.</title></caption>
<graphic mimetype="image" mime-subtype="tif" xlink:href="Biocell-47-25048-f002.tif"/>
</fig>
</sec>
<sec id="s4_3"><title>Insulin-like growth factor1 receptor promotes the warburg effect in ovarian cancer cells</title>
<p>In our previous studies, we showed that IGF1R is the direct target of miR-194-5p (<xref ref-type="bibr" rid="ref-3">Bai <italic>et al</italic>., 2020</xref>). Immunohistochemical analysis revealed that compared with normal ovarian tissues, IGF1R expression increased in ovarian cancer tissues (<xref ref-type="fig" rid="fig-3">Fig. 3A</xref>). To investigate the role of IGF1R in the Warburg effect, we knocked down IGF1R expression in ovarian cancer cells (<xref ref-type="fig" rid="fig-3">Fig. 3B</xref>) and found a decrease in ATP generation (<xref ref-type="fig" rid="fig-3">Fig. 3C</xref>), glucose uptake (<xref ref-type="fig" rid="fig-3">Fig. 3D</xref>), lactate production (<xref ref-type="fig" rid="fig-3">Fig. 3E</xref>) and ECAR level (<xref ref-type="fig" rid="fig-3">Figs. 3F</xref> and <xref ref-type="fig" rid="fig-3">3G</xref>). In agreement with that, ovarian cancer cells with reduced IGF1R expression showed decreased expression of PKM2, LDHA, GLUT1, and GLUT3 mRNA and proteins (<xref ref-type="fig" rid="fig-3">Figs. 3H</xref> and <xref ref-type="fig" rid="fig-3">3I</xref>). These results indicate that IGF1R promotes the Warburg effect in ovarian cancer cells.</p>
<fig id="fig-3">
<label>Figure 3</label>
<caption><title>IGF1R enhances the Warburg effect in ovarian cancer cells. (A) IGF1R expression in ovarian cancer tissues detected by immunohistochemical analysis. (B) The protein expression of IGF1R was examined by western blotting in the ovarian cells with knocked-down IGF1R expression. (C&#x2013;F) Quantification of ATP (C), level of glucose uptake (D), lactate concentration (E), ECAR (F), and glycolytic capacity (G) in the ovarian cells with inhibition of IGF1R expression. (H&#x2013;I) The mRNA expression (H) and protein expression (I) of PKM2, LDHA, GLUT1, and GLUT3 in the ovarian cells with inhibition of IGF1R expression. (&#x002A;<italic>P</italic> &#x003C; 0.05; &#x002A;&#x002A;<italic>P</italic> &#x003C; 0.01, &#x002A;&#x002A;&#x002A;<italic>P</italic> &#x003C; 0.001). IGF1R: insulin-like growth factor1 receptor; PKM2: pyruvate kinase M2; LDHA: lactate dehydrogenase A; GLUT: glucose transporter.</title></caption>
<graphic mimetype="image" mime-subtype="tif" xlink:href="Biocell-47-25048-f003.tif"/>
</fig>
</sec>
<sec id="s4_4"><title>MiR-194-5p regulates the insulin-like growth factor1 receptor/phosphatidylinositol-3-kinase/protein kinase B (IGF1R/PI3K/AKT) pathway in ovarian cancer cells</title>
<p>IGF1R and its downstream PI3K-AKT pathway serve as important regulators in the energy metabolism in tumor cells (<xref ref-type="bibr" rid="ref-2">Amutha and Rajkumar, 2017</xref>). To clarify whether the function of miR-194-5p on the Warburg effect is related to the IGF1R/PI3K/AKT signaling pathway, we tested AKT activation when IGF1R expression was knocked-down in ovarian cancer cells. The level of p-AKT decreased in the cells with reduced expression of IGF1R (<xref ref-type="fig" rid="fig-4">Fig. 4A</xref>). We further examined whether miR-194-5p contributes to the IGF1R/PI3K/AKT pathway and found that IGF1R expression and AKT activation decreased with miR-194-5p overexpression. In contrast, the knockdown of miR-194-5p expression increased the expression of these proteins (<xref ref-type="fig" rid="fig-4">Fig. 4B</xref>). These results further suggest that miR-194-5p mediates the PI3K/AKT pathway by targeting IGF1R in ovarian cancer cells. Taken together, our result reveals that miR-194-5p suppresses the Warburg effect in ovarian cancer cells through the PI3K/AKT signaling pathway by targeting IGF1R (<xref ref-type="fig" rid="fig-4">Fig. 4C</xref>).</p>
<fig id="fig-4">
<label>Figure 4</label>
<caption><title>miR-194-5p suppresses the IGF1R/PI3K/AKT pathway. (A) The protein level of AKT and p-AKT were detected by western blotting in the ovarian cells with IGF1R expression knocked down. (B) The protein level of IGF1R, p-AKT, and AKT in the ovarian cells overexpressing miR-194-5p or with knocked-down miR-194-5p expression. (C) The diagram of the mechanism of miR-194-5p regulates the Warburg effect in ovarian cancer cells. IGF1R/PI3K/AKT: insulin-like growth factor1 receptor/phosphatidylinositol-3-kinase/protein kinase B.</title></caption>
<graphic mimetype="image" mime-subtype="tif" xlink:href="Biocell-47-25048-f004.tif"/>
</fig>
</sec>
</sec>
<sec id="s5"><title>Discussion</title>
<p>In recent years, more studies have demonstrated that the Warburg effect plays a vital role in tumor cell progression, metastasis, and chemotherapy resistance (<xref ref-type="bibr" rid="ref-28">Vaupel <italic>et al</italic>., 2019</xref>; <xref ref-type="bibr" rid="ref-27">Icard <italic>et al</italic>., 2018</xref>). Therefore, blocking the Warburg effect is a new idea of molecular therapy against cancer (<xref ref-type="bibr" rid="ref-30">Pascale <italic>et al</italic>., 2020</xref>). However, the regulons and regulatory mechanism of the Warburg effect in tumor cells still need further investigation. MiRNAs serve as a key regulator of mRNA expression at the post-transcription level, and miRNAs are widely dysregulated in various types of cancer cells (<xref ref-type="bibr" rid="ref-29">Hill and Tran, 2021</xref>). A recent study supported that miRNAs control cancer-associated glycolytic processes through interaction with the key enzymes of glycolysis and cellular signaling pathway in cancers such as ovarian cancer (<xref ref-type="bibr" rid="ref-22">Zhang and Liu, 2022</xref>). For example, the expression of miR-203 is increased in ovarian cancer and promotes aerobic glycolysis by directly targeting the pyruvate dehydrogenase B (<xref ref-type="bibr" rid="ref-24">Zhao <italic>et al</italic>., 2016</xref>). Besides, miR-383 inhibits ovarian cancer cell proliferation, invasion, and glycolysis through the negative regulation of lactate dehydrogenase A (<xref ref-type="bibr" rid="ref-8">Han <italic>et al</italic>., 2017</xref>). MiR-603 overexpression suppresses the Warburg effect, and hexokinase-2 was identified as a target of miR-603 in ovarian cancer cells (<xref ref-type="bibr" rid="ref-12">Lu <italic>et al</italic>., 2019</xref>). In our study, upregulation of miR-194-5p in ovarian cancer cells suppresses the Warburg effect by decreasing ATP generation, glucose uptake, lactate production, and ECAR. This suggests that miR-194-5p contributes to the glycolytic metabolism of ovarian cancer cells. We further illustrated that miR-194-5p overexpression could suppress the PI3K/AKT signaling activity by negative regulation of IGF1R and inhibition of aerobic glycolysis in ovarian cancer cells.</p>
<p>IGF1R is frequently overexpressed in several tumor types, including ovarian cancer (<xref ref-type="bibr" rid="ref-15">Somri-Gannam <italic>et al</italic>., 2020</xref>; <xref ref-type="bibr" rid="ref-25">Zorea <italic>et al</italic>., 2018</xref>). The treatment of ovarian cancer cells with IGF1R monoclonal antibodies can significantly suppress the activity of IGF1R, resulting in cell growth inhibition and sensitivity to chemotherapy (<xref ref-type="bibr" rid="ref-23">Zhang <italic>et al</italic>., 2021</xref>). IGF1R binds to its ligands IGF1 or IGF2 and activates the PI3K/AKT signaling pathway (<xref ref-type="bibr" rid="ref-21">Werner and Sarfstein, 2014</xref>). Accumulated evidence suggests that the PI3K/AKT signaling is over-activated in human malignant tumors, in which glycolysis is increased by the upregulation of metabolic enzymes (<xref ref-type="bibr" rid="ref-6">Ediriweera <italic>et al</italic>., 2019</xref>). Furthermore, AKT activity increased in 40% of breast and ovarian cancers (<xref ref-type="bibr" rid="ref-11">Liu <italic>et al</italic>., 2018</xref>). AKT activity improves the accumulation of GLUT1 on the cell membrane and thus increases the uptake of glucose, which in turn promotes the Warburg effect (<xref ref-type="bibr" rid="ref-10">Hosios and Manning, 2021</xref>). Consistently, we revealed that miR-194-5p significantly suppresses IGF1R expression and AKT activity, which maybe, would result in the inhibition of aerobic glycolysis by miR-194-5p in ovarian cancer cells.</p>
<p>In conclusion, the present study revealed the role of miR-194-5p and its target gene, IGF1R, on aerobic glycolysis in ovarian cancer cells. MiR-194-5p suppressed aerobic glycolysis and negatively regulated IGF1R and the PI3K/AKT pathway. IGF1R promotes glycolysis in ovarian cancer cells. Therefore, miR-194-5p regulates aerobic glycolysis of ovarian cancer cells, possibly via IGF1R, which in turn affects the PI3K/AKT signaling pathway, suggesting the potential of miR-194-5p as a target in the treatment of ovarian cancer.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability"><title>Availability of Data and Materials</title>
<p>All data generated or analyzed during this study are included in this published article.</p>
</sec>
<sec><title>Author Contribution</title>
<p>Study conception and design: Ru Bai; data collection: Lijun Du and Kaikai Dou; analysis and interpretation of results: Lijun Du, Kaikai Dou, and Nianhai Liang; draft manuscript preparation: Lijun Du, Ru Bai, Jianmin Sun. All authors reviewed the results and approved the final version of the manuscript.</p>
</sec>
<sec><title>Ethics Approval</title>
<p>This study was approved by the Ethical Committee of Ningxia Medical University (Protocol No. 2020-007). The use of 25 fixed ovarian cancer tissues and 5 fixed normal ovarian tissues was approved by the Department of Pathology, General Hospital of Ningxia Medical University.</p>
</sec>
<sec><title>Funding Statement</title>
<p>This work was supported by the <funding-source>Nature Science Foundation of Ningxia</funding-source> (<award-id>2020AAC03162</award-id>).</p>
</sec>
<sec sec-type="COI-statement"><title>Conflicts of Interest</title>
<p>The authors declare that they have no conflicts of interest to report regarding the present study.</p>
</sec>
<ref-list content-type="authoryear"><title>References</title>
<ref id="ref-1"><label>Amin <italic>et al</italic>. (2019)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Amin</surname> <given-names>RW</given-names></string-name>, <string-name><surname>Ross</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>J</given-names></string-name>, <string-name><surname>Guy</surname> <given-names>J</given-names></string-name>, <string-name><surname>Stafford</surname> <given-names>B</given-names></string-name></person-group> (<year>2019</year>). <article-title>Patterns of ovarian cancer and uterine cancer mortality and incidence in the contiguous USA</article-title>. <source>Science of the Total Environment</source> <volume>697</volume>: <fpage>134128</fpage>. DOI <pub-id pub-id-type="doi">10.1016/j.scitotenv.2019.134128</pub-id>.</mixed-citation></ref>
<ref id="ref-2"><label>Amutha and Rajkumar (2017)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Amutha</surname> <given-names>P</given-names></string-name>, <string-name><surname>Rajkumar</surname> <given-names>T</given-names></string-name></person-group> (<year>2017</year>). <article-title>Role of insulin-like growth factor, insulin-like growth factor receptors, and insulin-like growth factor-binding proteins in ovarian cancer</article-title>. <source>Indian Journal of Medical and Paediatric Oncology</source> <volume>38</volume>: <fpage>198</fpage>&#x2013;<lpage>206</lpage>. DOI <pub-id pub-id-type="doi">10.4103/ijmpo.ijmpo_3_17</pub-id>.</mixed-citation></ref>
<ref id="ref-3"><label>Bai <italic>et al</italic>. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bai</surname> <given-names>R</given-names></string-name>, <string-name><surname>Dou</surname> <given-names>K</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ma</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>J</given-names></string-name></person-group> (<year>2020</year>). <article-title>The NF-&#x03BA;B modulated miR-194-5p/IGF1R/PPFIBP axis is crucial for the tumorigenesis of ovarian cancer</article-title>. <source>Journal of Cancer</source> <volume>11</volume>: <fpage>3433</fpage>&#x2013;<lpage>3445</lpage>. DOI <pub-id pub-id-type="doi">10.7150/jca.40604</pub-id>.</mixed-citation></ref>
<ref id="ref-4"><label>Cabasag <italic>et al</italic>. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cabasag</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Arnold</surname> <given-names>M</given-names></string-name>, <string-name><surname>Butler</surname> <given-names>J</given-names></string-name>, <string-name><surname>Inoue</surname> <given-names>M</given-names></string-name>, <string-name><surname>Trabert</surname> <given-names>B</given-names></string-name>, <string-name><surname>Webb</surname> <given-names>PM</given-names></string-name>, <string-name><surname>Bray</surname> <given-names>F</given-names></string-name>, <string-name><surname>Soerjomataram</surname> <given-names>I</given-names></string-name></person-group> (<year>2020</year>). <article-title>The influence of birth cohort and calendar period on global trends in ovarian cancer incidence</article-title>. <source>International Journal of Cancer</source> <volume>146</volume>: <fpage>749</fpage>&#x2013;<lpage>758</lpage>. DOI <pub-id pub-id-type="doi">10.1002/ijc.32322</pub-id>.</mixed-citation></ref>
<ref id="ref-5"><label>Coburn <italic>et al</italic>. (2017)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coburn</surname> <given-names>SB</given-names></string-name>, <string-name><surname>Bray</surname> <given-names>F</given-names></string-name>, <string-name><surname>Sherman</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Trabert</surname> <given-names>B</given-names></string-name></person-group> (<year>2017</year>). <article-title>International patterns and trends in ovarian cancer incidence, overall and by histologic subtype</article-title>. <source>International Journal of Cancer</source> <volume>140</volume>: <fpage>2451</fpage>&#x2013;<lpage>2460</lpage>. DOI <pub-id pub-id-type="doi">10.1002/ijc.30676</pub-id>.</mixed-citation></ref>
<ref id="ref-6"><label>Ediriweera <italic>et al</italic>. (2019)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ediriweera</surname> <given-names>MK</given-names></string-name>, <string-name><surname>Tennekoon</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Samarakoon</surname> <given-names>SR</given-names></string-name></person-group> (<year>2019</year>). <article-title>Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance</article-title>. <source>Seminars in Cancer Biology</source> <volume>59</volume>: <fpage>147</fpage>&#x2013;<lpage>160</lpage>. DOI <pub-id pub-id-type="doi">10.1016/j.semcancer.2019.05.012</pub-id>.</mixed-citation></ref>
<ref id="ref-26"><label>Ghafouri-Farda, Shooreib, Taheric. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Ghafouri-Farda S, Shooreib H, Taheric M</person-group> <year>(2020)</year>. miRNA profile in ovarian cancer. <source>Experimental and Molecular Pathology</source> <volume>113</volume>: <fpage>104381</fpage>. DOI <pub-id pub-id-type="doi">10.1016/j.yexmp.2020.104381</pub-id>.</mixed-citation></ref>
<ref id="ref-7"><label>Hanahan and Weinberg (2011)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hanahan</surname> <given-names>D</given-names></string-name>, <string-name><surname>Weinberg</surname> <given-names>RA</given-names></string-name></person-group> (<year>2011</year>). <article-title>Hallmarks of cancer: The next generation</article-title>. <source>Cell</source> <volume>144</volume>: <fpage>646</fpage>&#x2013;<lpage>674</lpage>. DOI <pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id>.</mixed-citation></ref>
<ref id="ref-8"><label>Han <italic>et al</italic>. (2017)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>FP</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>XY</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Y</given-names></string-name></person-group> (<year>2017</year>). <article-title>miR-383 inhibits ovarian cancer cell proliferation, invasion and aerobic glycolysis by targeting LDHA</article-title>. <source>Neoplasma</source> <volume>64</volume>: <fpage>244</fpage>&#x2013;<lpage>252</lpage>. DOI <pub-id pub-id-type="doi">10.4149/neo_2017_211</pub-id>.</mixed-citation></ref>
<ref id="ref-9"><label>He and Hannon (2004)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname> <given-names>L</given-names></string-name>, <string-name><surname>Hannon</surname> <given-names>GJ</given-names></string-name></person-group> (<year>2004</year>). <article-title>MicroRNAs: Small RNAs with a big role in gene regulation</article-title>. <source>Nature Reviews Genetics</source> <volume>5</volume>: <fpage>522</fpage>&#x2013;<lpage>531</lpage>. DOI <pub-id pub-id-type="doi">10.1038/nrg1379</pub-id>.</mixed-citation></ref>
<ref id="ref-29"><label>Hill and Tran (2021)</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Hill M, Tran N</person-group> (<year>2021</year>). <article-title>miRNA interplay: Mechanisms and consequences in cancer</article-title>. <source>Disease Models &#x0026; Mechanisms</source> <volume>14</volume>: <fpage>1</fpage>&#x2013;<lpage>9</lpage>. DOI <pub-id pub-id-type="doi">10.1242/dmm.047662</pub-id>.</mixed-citation></ref>
<ref id="ref-10"><label>Hosios and Manning (2021)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hosios</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Manning</surname> <given-names>BD</given-names></string-name></person-group> (<year>2021</year>). <article-title>Cancer signaling drives cancer metabolism: AKT and the warburg effect</article-title>. <source>Cancer Research</source> <volume>81</volume>: <fpage>4896</fpage>&#x2013; <lpage>4898</lpage>. DOI <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-21-2647</pub-id>.</mixed-citation></ref>
<ref id="ref-27"><label>Icard <italic>et al</italic>. (2018)</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M, Lincet H</person-group> (<year>2018</year>). <article-title>How the Warburg effect supports aggressiveness and drug resistance of cancer cells?</article-title> <source>Drug Resistance Updates</source> <volume>38</volume>: <fpage>1</fpage>&#x2013;<lpage>11</lpage>. DOI <pub-id pub-id-type="doi">10.1016/j.drup.2018.03.001</pub-id>.</mixed-citation></ref>
<ref id="ref-11"><label>Liu <italic>et al</italic>. (2018)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname> <given-names>HW</given-names></string-name>, <string-name><surname>Bi</surname> <given-names>WT</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>HT</given-names></string-name>, <string-name><surname>Li</surname> <given-names>RX</given-names></string-name>, <string-name><surname>Xi</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Feng</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bo</surname> <given-names>W</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wen</surname> <given-names>WS</given-names></string-name></person-group> (<year>2018</year>). <article-title>Satb1 promotes Schwann cell viability and migration via activation of PI3K/AKT pathway</article-title>. <source>European Review for Medical and Pharmacological Sciences</source> <volume>22</volume>: <fpage>4268</fpage>&#x2013;<lpage>4277</lpage>. DOI <pub-id pub-id-type="doi">10.26355/eurrev_201807_15423</pub-id>.</mixed-citation></ref>
<ref id="ref-12"><label>Lu <italic>et al</italic>. (2019)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>W</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhen</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>H</given-names></string-name>, <string-name><surname>Cheng</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Li</surname> <given-names>X</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>L</given-names></string-name></person-group> (<year>2019</year>). <article-title>miR-603 targeted hexokinase-2 to inhibit the malignancy of ovarian cancer cells</article-title>. <source>Archives of Biochemistry and Biophysics</source> <volume>661</volume>: <fpage>1</fpage>&#x2013;<lpage>9</lpage>. DOI <pub-id pub-id-type="doi">10.1016/j.abb.2018.10.014</pub-id>.</mixed-citation></ref>
<ref id="ref-13"><label>Park <italic>et al</italic>. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Pyun</surname> <given-names>WY</given-names></string-name>, <string-name><surname>Park</surname> <given-names>HW</given-names></string-name></person-group> (<year>2020</year>). <article-title>Cancer metabolism: Phenotype, signaling and therapeutic targets</article-title>. <source>Cells</source> <volume>9</volume>: <fpage>2308</fpage>. DOI <pub-id pub-id-type="doi">10.3390/cells9102308</pub-id>.</mixed-citation></ref>
<ref id="ref-30"><label>Pascale <italic>et al</italic>. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Pascale RM, Calvisi DF, Simile MM, Feo CF, Feo F</person-group> (<year>2020</year>). <article-title>The Warburg effect 97 years after its discovery</article-title>. <source>Cancers</source> <volume>12</volume>: <fpage>2819</fpage>. DOI <pub-id pub-id-type="doi">10.3390/cancers12102819</pub-id>.</mixed-citation></ref>
<ref id="ref-14"><label>Saliminejad <italic>et al</italic>. (2019)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saliminejad</surname> <given-names>K</given-names></string-name>, <string-name><surname>Khorram Khorshid</surname> <given-names>HR</given-names></string-name>, <string-name><surname>Soleymani Fard</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ghaffari</surname> <given-names>SH</given-names></string-name></person-group> (<year>2019</year>). <article-title>An overview of microRNAs: Biology, functions, therapeutics, and analysis methods</article-title>. <source>Journal of Cellular Physiology</source> <volume>234</volume>: <fpage>5451</fpage>&#x2013;<lpage>5465</lpage>. DOI <pub-id pub-id-type="doi">10.1002/jcp.27486</pub-id>.</mixed-citation></ref>
<ref id="ref-15"><label>Somri-Gannam <italic>et al</italic>. (2020)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Somri-Gannam</surname> <given-names>L</given-names></string-name>, <string-name><surname>Meisel-Sharon</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hantisteanu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Groisman</surname> <given-names>G</given-names></string-name>, <string-name><surname>Limonad</surname> <given-names>O</given-names></string-name>, <string-name><surname>Hallak</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bruchim</surname> <given-names>I</given-names></string-name></person-group> (<year>2020</year>). <article-title>IGF1R axis inhibition restores dendritic cell antitumor response in ovarian cancer</article-title>. <source>Translational Oncology</source> <volume>13</volume>: <fpage>100790</fpage>. DOI <pub-id pub-id-type="doi">10.1016/j.tranon.2020.100790</pub-id>.</mixed-citation></ref>
<ref id="ref-16"><label>Torre <italic>et al</italic>. (2018)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Torre</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Trabert</surname> <given-names>B</given-names></string-name>, <string-name><surname>DeSantis</surname> <given-names>CE</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>KD</given-names></string-name>, <string-name><surname>Samimi</surname> <given-names>G</given-names></string-name>, <string-name><surname>Runowicz</surname> <given-names>CD</given-names></string-name>, <string-name><surname>Gaudet</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Jemal</surname> <given-names>A</given-names></string-name>, <string-name><surname>Siegel</surname> <given-names>RL</given-names></string-name></person-group> (<year>2018</year>). <article-title>Ovarian cancer statistics, 2018</article-title>. <source>CA: A Cancer Journal for Clinicians</source> <volume>68</volume>: <fpage>284</fpage>&#x2013;<lpage>296</lpage>. DOI <pub-id pub-id-type="doi">10.3322/caac.21456</pub-id>.</mixed-citation></ref>
<ref id="ref-17"><label>Tsibulak <italic>et al</italic>. (2019)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tsibulak</surname> <given-names>I</given-names></string-name>, <string-name><surname>Zeimet</surname> <given-names>AG</given-names></string-name>, <string-name><surname>Marth</surname> <given-names>C</given-names></string-name></person-group> (<year>2019</year>). <article-title>Hopes and failures in front-line ovarian cancer therapy</article-title>. <source>Critical Reviews in Oncology/Hematology</source> <volume>143</volume>: <fpage>14</fpage>&#x2013;<lpage>19</lpage>. DOI <pub-id pub-id-type="doi">10.1016/j.critrevonc.2019.08.002</pub-id>.</mixed-citation></ref>
<ref id="ref-18"><label>Vaupel and Multhoff (2021)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vaupel</surname> <given-names>P</given-names></string-name>, <string-name><surname>Multhoff</surname> <given-names>G</given-names></string-name></person-group> (<year>2021</year>). <article-title>Revisiting the Warburg effect: Historical dogma <italic>vs.</italic> current understanding</article-title>. <source>The Journal of Physiology</source> <volume>599</volume>: <fpage>1745</fpage>&#x2013;<lpage>1757</lpage>. DOI <pub-id pub-id-type="doi">10.1113/JP278810</pub-id>.</mixed-citation></ref>
<ref id="ref-28"><label>Vaupel, Schmidberger, Mayer. (2019)</label><mixed-citation publication-type="journal"><person-group person-group-type="author">Vaupel P, Schmidberger H, Mayer A</person-group> (<year>2019</year>). <article-title>The Warburg effect: Essential part of metabolic reprogramming and central contributor to cancer progression</article-title>. <source>International Journal of Radiation Biology</source> <volume>95</volume>: <fpage>912</fpage>&#x2013;<lpage>919</lpage>. DOI <pub-id pub-id-type="doi">10.1080/09553002.2019.1589653</pub-id>.</mixed-citation></ref>
<ref id="ref-19"><label>Vazquez <italic>et al</italic>. (2016)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vazquez</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kamphorst</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Markert</surname> <given-names>EK</given-names></string-name>, <string-name><surname>Schug</surname> <given-names>ZT</given-names></string-name>, <string-name><surname>Tardito</surname> <given-names>S</given-names></string-name>, <string-name><surname>Gottlieb</surname> <given-names>E</given-names></string-name></person-group> (<year>2016</year>). <article-title>Cancer metabolism at a glance</article-title>. <source>Journal of Cell Science</source> <volume>129</volume>: <fpage>3367</fpage>&#x2013;<lpage>3373</lpage>. DOI <pub-id pub-id-type="doi">10.1242/jcs.181016</pub-id>.</mixed-citation></ref>
<ref id="ref-20"><label>Vishnoi and Rani (2017)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vishnoi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Rani</surname> <given-names>S</given-names></string-name></person-group> (<year>2017</year>). <article-title>MiRNA biogenesis and regulation of diseases: An overview</article-title>. <source>Methods in Molecular Biology</source> <volume>1509</volume>: <fpage>1</fpage>&#x2013;<lpage>10</lpage>. DOI <pub-id pub-id-type="doi">10.1007/978-1-4939-6524-3</pub-id>.</mixed-citation></ref>
<ref id="ref-21"><label>Werner and Sarfstein (2014)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Werner</surname> <given-names>H</given-names></string-name>, <string-name><surname>Sarfstein</surname> <given-names>R</given-names></string-name></person-group> (<year>2014</year>). <article-title>Transcriptional and epigenetic control of IGF1R gene expression: Implications in metabolism and cancer</article-title>. <source>Growth Hormone &#x0026; IGF Research</source> <volume>24</volume>: <fpage>112</fpage>&#x2013;<lpage>118</lpage>. DOI <pub-id pub-id-type="doi">10.1016/j.ghir.2014.03.006</pub-id>.</mixed-citation></ref>
<ref id="ref-22"><label>Zhang and Liu (2022)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>N</given-names></string-name></person-group> (<year>2022</year>). <article-title>Noncoding RNAs in the glycolysis of ovarian cancer</article-title>. <source>Frontiers in Pharmacology</source> <volume>13</volume>: <fpage>855488</fpage>. DOI <pub-id pub-id-type="doi">10.3389/fphar.2022.855488</pub-id>.</mixed-citation></ref>
<ref id="ref-23"><label>Zhang <italic>et al</italic>. (2021)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Jia</surname> <given-names>J</given-names></string-name>, <string-name><surname>Bai</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>R</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>C</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>R</given-names></string-name></person-group> (<year>2021</year>). <article-title>IGF-1R anti-idiotypic antibody antagonist exhibited anti-ovarian cancer bioactivity and reduced cisplatin resistance</article-title>. <source>Human Cell</source> <volume>3</volume>: <fpage>1197</fpage>&#x2013;<lpage>1214</lpage>. DOI <pub-id pub-id-type="doi">10.1007/s13577-021-00535-x</pub-id>.</mixed-citation></ref>
<ref id="ref-24"><label>Zhao <italic>et al</italic>. (2016)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname> <given-names>X</given-names></string-name>, <string-name><surname>Fan</surname> <given-names>L</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>N</given-names></string-name>, <string-name><surname>Zou</surname> <given-names>K</given-names></string-name>, <string-name><surname>Xiao</surname> <given-names>X</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>S</given-names></string-name></person-group> (<year>2016</year>). <article-title>MiR-203 promotes the growth and migration of ovarian cancer cells by enhancing glycolytic pathway</article-title>. <source>Tumor Biology</source> <volume>37</volume>: <fpage>14989</fpage>&#x2013;<lpage>14997</lpage>. DOI <pub-id pub-id-type="doi">10.1007/s13277-016-5415-1</pub-id>.</mixed-citation></ref>
<ref id="ref-25"><label>Zorea <italic>et al</italic>. (2018)</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zorea</surname> <given-names>J</given-names></string-name>, <string-name><surname>Prasad</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cohen</surname> <given-names>L</given-names></string-name>, <string-name><surname>Li</surname> <given-names>N</given-names></string-name>, <string-name><surname>Schefzik</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ghosh</surname> <given-names>S</given-names></string-name>, <string-name><surname>Rotblat</surname> <given-names>B</given-names></string-name>, <string-name><surname>Brors</surname> <given-names>B</given-names></string-name>, <string-name><surname>Elkabets</surname> <given-names>M</given-names></string-name></person-group> (<year>2018</year>). <article-title>IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer</article-title>. <source>Cell Death &#x0026; Disease</source> <volume>9</volume>: <fpage>944</fpage>. DOI <pub-id pub-id-type="doi">10.1038/s41419-018-1025-8</pub-id>.</mixed-citation></ref>
</ref-list>
</back>
</article>